Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors, including Pancreatic Cancer
The purpose of this phase I/II study is to evaluate the safety and feasibility of CM24 in combination with nivolumab and nab-paclitaxel in patients with pancreatic cancer.
Study ID: FW-2020-1
Trial Phase: Phase I/II
Trial Sponsor: Famewave Ltd.
Therapies Used in This Trial: Nab-paclitaxel, Nivolumab, CM-24